

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

C5AR1 RABBIT PAB

货号: S218415 产品全名: C5ARI 兔多抗 基因符号 C5A; C5AR; C5RI; CD88 UNIPROT ID: P21730 (Gene Accession - BC008982) 端晷: Recentor for the chamatactic and informatic

背景: Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a (PubMed:1847994, PubMed:18182049, PubMed:7622471, PubMed:9553099, PubMed:10636859, PubMed:15153520). The ligand interacts with at least two sites on the receptor: a high-affinity site on the extracellular N-terminus, and a second site in the transmembrane region which activates downstream signaling events (PubMed:18182049, PubMed:7622471, PubMed:9553099). Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production (PubMed:10636859, PubMed:15153520).

抗原: Fusion protein of human C5AR1

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 40-200; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化:Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism, Signal Transduction, Immunology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 218415(C5AR1 Antibody) at a dilution of 1/50(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 218415(Anti-C5AR1 Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffinembedded Human esophagus cancer tissue using 218415(Anti-C5ARI Antibody) at a dilution of 1/50.



In comparision with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with fusion protein and then with D224365(Anti-C5ARI Antibody) at dilution 1/50.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010